On the public citation graph
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
0 signed · 3038 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-jopenalex-snapshot
Hepatitis B virus.The major etiology of hepatocellular carcinoma
inferredcites →https://doi.org/10.1002/hep.1840120406openalex-snapshot
Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children
inferredcites →https://doi.org/10.1002/hep.1840220508openalex-snapshot
The significance of spontaneous hepatitis B e antigen seroconversion in childhood: With special emphasis on the clearance of hepatitis B e antigen before 3 years of age
inferredcites →https://doi.org/10.1002/hep.1840360617openalex-snapshot
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection
inferredcites →https://doi.org/10.1016/0378-3758(93)90088-nopenalex-snapshot
Small sample and efficiency results for the Nelson-Aalen estimator
inferredcites →https://doi.org/10.1046/j.1440-1746.2000.02124.xopenalex-snapshot
Epidemiology of hepatitis B virus infection in the Asia–Pacific region
inferredcites →https://doi.org/10.1046/j.1440-1746.2003.03037.xopenalex-snapshot
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
inferredcites →https://doi.org/10.1053/jhep.2002.37084openalex-snapshot
Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: Multistage hepatocarcinogenesis with multifactorial etiology
inferredcites →https://doi.org/10.1053/jhep.2003.50099openalex-snapshot
Antiviral Therapy in Hbe–Ag-Positive Hepatitis B With Normal Aminotransferase Levels
inferredcites →https://doi.org/10.1053/jhep.2003.50208openalex-snapshot
Serum Hbv Dna As A Marker of Efficacy During Therapy for Chronic Hbv Infection: Analysis and Review of the Literature
inferredcites →https://doi.org/10.1053/jhep.2003.50280openalex-snapshot
Can Serum Hbv–Dna Be Used As A Primary End Point to Assess Efficacy of New Treatments for Chronic Hepatitis B?
inferredcites →https://doi.org/10.1056/nejm199712113372406openalex-snapshot
Hepatitis B Virus Infection
inferredcites →https://doi.org/10.1056/nejm200211213472120openalex-snapshot
Troponin T Levels and Acute Coronary Syndromes
inferredcites →https://doi.org/10.1056/nejmoa013215openalex-snapshot
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1080/07853890310021580openalex-snapshot
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma
inferredcites →https://doi.org/10.1093/jnci/dji043openalex-snapshot
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
inferredcites →https://doi.org/10.1111/j.1440-1746.1997.tb00513.xopenalex-snapshot
Epidemiological characteristics and risk factors of hepatocellular carcinoma
inferredcites →https://doi.org/10.1214/aos/1176342705openalex-snapshot
A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship
inferredcites →https://doi.org/10.1214/aos/1176344247openalex-snapshot
Nonparametric Inference for a Family of Counting Processes
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4472080openalex-extracted
Hepatocellular Carcinoma Risk in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B Living in Europe: An International Multicenter Retrospective Cohort Study
inferred← citesno DOI in the source recordopenalex-snapshot
Staphylococcal nasal carriage of health care workers.
inferred← citeshttps://doi.org/10.1001/2012.jama.11975openalex-snapshot
Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver Resection
inferred← citeshttps://doi.org/10.1001/archsurg.2011.125openalex-snapshot
Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus–Related Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1001/jama.2012.12971openalex-snapshot
Does Antiviral Therapy Prevent Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Curative Liver Resection?
inferred← citeshttps://doi.org/10.1001/jama.2019.8252openalex-snapshot
Hepatitis B Screening in Pregnant Women
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2019.5718openalex-snapshot
Associations Between Hepatitis B Virus Infection and Risk of All Cancer Types
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.19407openalex-snapshot
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.23511openalex-snapshot
Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus–Related Cirrhosis
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.42744openalex-snapshot
Hepatitis B Virus Treatment Gaps in the US
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.0035openalex-snapshot
Association of High Body Mass Index and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4039openalex-snapshot
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.4070openalex-snapshot
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/14651858.cd006572openalex-snapshot
Entecavir for chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/14651858.cd006572.pub2openalex-snapshot
Entecavir for chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/14651858.cd008713openalex-snapshot
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/14651858.cd008713.pub2openalex-snapshot
Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/14651858.cd015730openalex-snapshot
Combination treatment of pegylated interferon and tenofovir versus tenofovir for people with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/9780470747919.ch52openalex-snapshot
Clinical Implications of the Molecular Biology of Hepatitis B Virus
inferred← citeshttps://doi.org/10.1002/9780470929353.ch28openalex-snapshot
Discovery and Development of Entecavir
inferred← citeshttps://doi.org/10.1002/9781118314968.ch13openalex-snapshot
Chronic Viral Hepatitis in Adults and Children: Hepatitis B
inferred← citeshttps://doi.org/10.1002/9781118512074.ch95openalex-snapshot
Chronic Hepatitis B Viral Infection
inferred← citeshttps://doi.org/10.1002/9781118637272.ch10openalex-snapshot
Natural History of Chronic Hepatitis B Virus Infection
inferred← citeshttps://doi.org/10.1002/9781118826621.ch13openalex-snapshot
Hepatitis Viruses and Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm031.pub2openalex-snapshot
Hepatitis Viruses and Hepatoma
inferred← citeshttps://doi.org/10.1002/9781119211419.ch33openalex-snapshot
Hepatitis B : Prognosis and Treatment
inferred← citeshttps://doi.org/10.1002/9781119436812.ch59openalex-snapshot
Epidemiology of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/9781119436812.ch64openalex-snapshot
Clinical Implications of the Molecular Biology of Hepatitis B Virus
inferred← citeshttps://doi.org/10.1002/9781119533481.ch38openalex-snapshot
Hepatitis B virus diagnostics: anything new?
inferred← citeshttps://doi.org/10.1002/9781119756422.ch16openalex-snapshot
Screening, Surveillance, and Prevention of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/9781444319590.ch27openalex-snapshot
Rethinking the Inactive Carrier State: Management of Patients with Low‐Replicative HBeAg‐Negative Chronic Hepatitis B and Normal Liver Enzymes
inferred← citeshttps://doi.org/10.1002/9781444319590.ch28openalex-snapshot
HBeAg‐Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy
inferred← citeshttps://doi.org/10.1002/advs.202514172openalex-snapshot
TRMT6‐Mediated m 1 A Modification of CDK9 mRNA is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/aid2.12012openalex-snapshot
Serum vitamin D level not correlated with hepatitis B virus replication in patients with chronic hepatitis B virus infection
inferred← citeshttps://doi.org/10.1002/aid2.13356openalex-snapshot
The impact of early hepatitis B virus viral suppression on treatment response in entecavir‐treated hepatitis B e antigen‐positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/aid2.13424openalex-snapshot
Decreased incidence of hepatocellular carcinoma in non‐cirrhotic and low‐viral‐load chronic hepatitis B patients treated with nucleotide/nucleoside analogs
inferred← citeshttps://doi.org/10.1002/aid2.70011openalex-snapshot
Treatment in noncirrhotic and low‐viral‐load chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/bies.201200099openalex-snapshot
Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases
inferred← citeshttps://doi.org/10.1002/cam4.2380openalex-snapshot
Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization
inferred← citeshttps://doi.org/10.1002/cam4.5694openalex-snapshot
The role of viruses in cancer development versus cancer therapy: An oncological perspective
inferred← citeshttps://doi.org/10.1002/cam4.712openalex-snapshot
Hepatitis B virus mutations, expression quantitative trait loci for PTPN 12, and their interactions in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/cam4.71887openalex-snapshot
An XGBoost ‐Based Multicenter Model for Predicting HBV ‐Related Hepatocellular Carcinoma: Development and Validation
inferred← citeshttps://doi.org/10.1002/ccr3.3360openalex-snapshot
Hepatitis B virus core–related antigen is useful for surveillance of hepatocellular carcinoma recurrence in a patient with occult hepatitis B virus infection: Case report
inferred← citeshttps://doi.org/10.1002/cld.111openalex-snapshot
Risk factors for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/cld.1125openalex-snapshot
Chronic Hepatitis B: Challenges and Successes in India
inferred← citeshttps://doi.org/10.1002/cld.117openalex-snapshot
Molecular epidemiology of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/cld.160openalex-snapshot
Hepatitis B virus treatment: Which patients can have treatment deferred?
inferred← citeshttps://doi.org/10.1002/cld.483openalex-snapshot
Personalized management of hepatocellular carcinoma based on molecular information: Future prospects
inferred← citeshttps://doi.org/10.1002/cld.601openalex-snapshot
Tratamiento personalizado del carcinoma hepatocelular basado en información molecular: perspectivas futuras
inferred← citeshttps://doi.org/10.1002/cld.892openalex-snapshot
PRO: Patients With Chronic Hepatitis B in Immune‐Tolerant Phase Should Be Treated
inferred← citeshttps://doi.org/10.1002/cld.893openalex-snapshot
CON: All Patients With Immune‐Tolerated Hepatitis B Virus Do Not Need to Be Treated
inferred← citeshttps://doi.org/10.1002/cld.904openalex-snapshot
Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time
inferred← citeshttps://doi.org/10.1002/cncr.22242openalex-snapshot
Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high‐risk for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/cncr.22984openalex-snapshot
The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization
inferred← citeshttps://doi.org/10.1002/cncr.25837openalex-snapshot
A clustered ground‐glass hepatocyte pattern represents a new prognostic marker for the recurrence of hepatocellular carcinoma after surgery
inferred← citeshttps://doi.org/10.1002/cncr.29159openalex-snapshot
Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population‐based cohort study
inferred← citeshttps://doi.org/10.1002/cncr.29537openalex-snapshot
Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/cncr.31134openalex-snapshot
Efficacy of a community‐based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans
inferred← citeshttps://doi.org/10.1002/hep.21373openalex-snapshot
Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference
inferred← citeshttps://doi.org/10.1002/hep.21572openalex-snapshot
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy
inferred← citeshttps://doi.org/10.1002/hep.21585openalex-snapshot
Hepatitis B viral factors in HBeAg‐Negative carriers with persistently normal serum alanine aminotransferase levels†
inferred← citeshttps://doi.org/10.1002/hep.21621openalex-snapshot
Causes of death in hepatitis B and/or C virus infected–people—lessons for clinical practice†
inferred← citeshttps://doi.org/10.1002/hep.21724openalex-snapshot
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†
inferred← citeshttps://doi.org/10.1002/hep.21758openalex-snapshot
Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients
inferred← citeshttps://doi.org/10.1002/hep.21784openalex-snapshot
Why we should routinely screen Asian American adults for hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.21893openalex-snapshot
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/hep.21939openalex-snapshot
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response
inferred← citeshttps://doi.org/10.1002/hep.22065openalex-snapshot
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.22075openalex-snapshot
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial
inferred← citeshttps://doi.org/10.1002/hep.22323openalex-snapshot
Entecavir therapy for lamivudine‐refractory chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.22330openalex-snapshot
Hepatitis B virus genotype: A missing link in transmission risk and disease progression?
inferred← citeshttps://doi.org/10.1002/hep.22414openalex-snapshot
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.22432openalex-snapshot
Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening
inferred← citeshttps://doi.org/10.1002/hep.22469openalex-snapshot
Virion half‐life in chronic hepatitis B infection is strongly correlated with levels of viremia†
inferred← citeshttps://doi.org/10.1002/hep.22658openalex-snapshot
Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.22714openalex-snapshot
Revisiting the treatment recommendations for chronic hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.22755openalex-snapshot
Hepatitis B virus viral load and treatment decision #
inferred← citeshttps://doi.org/10.1002/hep.22765openalex-snapshot
Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-β signaling from tumor suppression to oncogenesis in early chronic hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.22878openalex-snapshot
Long‐term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time†
inferred← citeshttps://doi.org/10.1002/hep.22884openalex-snapshot
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B # †
inferred← citeshttps://doi.org/10.1002/hep.22898openalex-snapshot
The natural history of chronic hepatitis B virus infection #
inferred← citeshttps://doi.org/10.1002/hep.22899openalex-snapshot
Monitoring during and after antiviral therapy for hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.22920openalex-snapshot
Benefits and risks of nucleoside analog therapy for hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.22929openalex-snapshot
Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence # †
inferred← citeshttps://doi.org/10.1002/hep.22931openalex-snapshot
Indications for therapy in hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.22962openalex-snapshot
Hepatitis B and hepatocellular carcinoma #
inferred← citeshttps://doi.org/10.1002/hep.22977openalex-snapshot
Endpoints of therapy in chronic hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.23110openalex-snapshot
A call for attention and trials on hepatitis B e antigen–negative, alanine aminotransferase–normal chronic hepatitis B virus infection†
inferred← citeshttps://doi.org/10.1002/hep.23147openalex-snapshot
A novel role for human leukocyte antigen‐DP in chronic hepatitis B infection
inferred← citeshttps://doi.org/10.1002/hep.23163openalex-snapshot
Identification of androgen response elements in the enhancer I of hepatitis B virus: A mechanism for sex disparity in chronic hepatitis B #
inferred← citeshttps://doi.org/10.1002/hep.23310openalex-snapshot
Cost-Effectiveness of Nationwide Hepatitis B Catch-Up Vaccination Among Children and Adolescents in China
inferred← citeshttps://doi.org/10.1002/hep.23327openalex-snapshot
Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.23346openalex-snapshot
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function†
inferred← citeshttps://doi.org/10.1002/hep.23348openalex-snapshot
Age-Specific Prognosis Following Spontaneous Hepatitis B E Antigen Seroconversion in Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.23505openalex-snapshot
Estimation of the Healthy Upper Limits for Serum Alanine Aminotransferase in Asian Populations With Normal Liver Histology
inferred← citeshttps://doi.org/10.1002/hep.23567openalex-snapshot
Nonobese Population in A Developing Country Has A High Prevalence of Nonalcoholic Fatty Liver and Significant Liver Disease
inferred← citeshttps://doi.org/10.1002/hep.23568openalex-snapshot
Durability of Peginterferon Alfa-2B Treatment at 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.23722openalex-snapshot
Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†
inferred← citeshttps://doi.org/10.1002/hep.23785openalex-snapshot
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡
inferred← citeshttps://doi.org/10.1002/hep.23844openalex-snapshot
Prediction of Sustained Response to Peginterferon Alfa-2b for Hepatitis B e Antigen–Positive Chronic Hepatitis B Using on-Treatment Hepatitis B Surface Antigen Decline
inferred← citeshttps://doi.org/10.1002/hep.23934openalex-snapshot
Treatment of Children With Chronic Hepatitis B Virus Infection in the United States
inferred← citeshttps://doi.org/10.1002/hep.24121openalex-snapshot
Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σ
inferred← citeshttps://doi.org/10.1002/hep.24150openalex-snapshot
Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: A cohort study of parous women in Taiwan
inferred← citeshttps://doi.org/10.1002/hep.24163openalex-snapshot
Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication
inferred← citeshttps://doi.org/10.1002/hep.24221openalex-snapshot
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir
inferred← citeshttps://doi.org/10.1002/hep.24363openalex-snapshot
Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy
inferred← citeshttps://doi.org/10.1002/hep.24434openalex-snapshot
Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes
inferred← citeshttps://doi.org/10.1002/hep.24500openalex-snapshot
Fighting against viral hepatitis: Lessons from Taiwan
inferred← citeshttps://doi.org/10.1002/hep.24502openalex-snapshot
Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair
inferred← citeshttps://doi.org/10.1002/hep.24615openalex-snapshot
Determinants of Spontaneous Surface Antigen Loss in Hepatitis B E Antigen–Negative Patients With A Low Viral Load
inferred← citeshttps://doi.org/10.1002/hep.25636openalex-snapshot
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.26041openalex-snapshot
Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads
inferred← citeshttps://doi.org/10.1002/hep.26138openalex-snapshot
Whither hepatocellular carcinoma screening?
inferred← citeshttps://doi.org/10.1002/hep.26180openalex-snapshot
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
inferred← citeshttps://doi.org/10.1002/hep.26277openalex-snapshot
Efficacy of Tenofovir Disoproxil Fumarate At 240 Weeks in Patients With Chronic Hepatitis B With High Baseline Viral Load
inferred← citeshttps://doi.org/10.1002/hep.26317openalex-snapshot
Does hepatitis B treatment reduce the incidence of hepatocellular carcinoma?
inferred← citeshttps://doi.org/10.1002/hep.26385openalex-snapshot
Prediction Models of Long-Term Cirrhosis and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: Risk Scores Integrating Host and Virus Profiles
inferred← citeshttps://doi.org/10.1002/hep.26436openalex-snapshot
Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels
inferred← citeshttps://doi.org/10.1002/hep.26910openalex-snapshot
Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy
inferred← citeshttps://doi.org/10.1002/hep.26934openalex-snapshot
Population Health Impact and Cost-Effectiveness of Monitoring Inactive Chronic Hepatitis B and Treating Eligible Patients in Shanghai, China
inferred← citeshttps://doi.org/10.1002/hep.27083openalex-snapshot
Distinct Seromarkers Predict Different Milestones of Chronic Hepatitis B Progression
inferred← citeshttps://doi.org/10.1002/hep.27337openalex-snapshot
Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus‐infected patients
inferred← citeshttps://doi.org/10.1002/hep.27630openalex-snapshot
Significant reduction in end‐stage liver diseases burden through the national viral hepatitis therapy program in Taiwan
inferred← citeshttps://doi.org/10.1002/hep.27765openalex-snapshot
Risk scores for hepatocellular carcinoma in chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.27889openalex-snapshot
Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load
inferred← citeshttps://doi.org/10.1002/hep.27947openalex-snapshot
Hepatitis C virus addiction to liver miR‐122 takes its Toll on the host
inferred← citeshttps://doi.org/10.1002/hep.28015openalex-snapshot
Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.28110openalex-snapshot
Diabetes and prediabetes in patients with hepatitis B residing in North America
inferred← citeshttps://doi.org/10.1002/hep.28115openalex-snapshot
Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy
inferred← citeshttps://doi.org/10.1002/hep.28118openalex-snapshot
Hepatoma in hepatitis B: Infectious disease or liver disease?
inferred← citeshttps://doi.org/10.1002/hep.28156openalex-snapshot
AASLD guidelines for treatment of chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.28266openalex-snapshot
Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus–related hepatocellular carcinoma after radiofrequency ablation
inferred← citeshttps://doi.org/10.1002/hep.28280openalex-snapshot
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/hep.28310openalex-snapshot
Cost‐effectiveness of active‐passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection
inferred← citeshttps://doi.org/10.1002/hep.28552openalex-snapshot
Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
inferred← citeshttps://doi.org/10.1002/hep.28654openalex-snapshot
Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/hep.29187openalex-snapshot
Monotherapy with tenofovir disoproxil fumarate for multiple drug‐resistant chronic hepatitis B: 3‐year trial
inferred← citeshttps://doi.org/10.1002/hep.29192openalex-snapshot
Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study
inferred← citeshttps://doi.org/10.1002/hep.29235openalex-snapshot
Low‐level viremia in hepatitis b patients on antiviral treatment: Can we ignore it?
inferred← citeshttps://doi.org/10.1002/hep.29323openalex-snapshot
Hepatitis B cure: From discovery to regulatory approval
inferred← citeshttps://doi.org/10.1002/hep.29463openalex-snapshot
Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant
inferred← citeshttps://doi.org/10.1002/hep.29874openalex-snapshot
Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance
inferred← citeshttps://doi.org/10.1002/hep.29913openalex-snapshot
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
inferred← citeshttps://doi.org/10.1002/hep.30339openalex-snapshot
Smoking and Hepatitis B Virus–Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase
inferred← citeshttps://doi.org/10.1002/hep.31008openalex-snapshot
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
inferred← citeshttps://doi.org/10.1002/hep.31267openalex-snapshot
Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/hep.31481openalex-snapshot
Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/hep.31554openalex-snapshot
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy
inferred← citeshttps://doi.org/10.1002/hep.31612openalex-snapshot
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
inferred← citeshttps://doi.org/10.1002/hep.31839openalex-snapshot
Risk of HCC With Hepatitis B Viremia Among HIV/HBV‐Coinfected Persons in North America
inferred← citeshttps://doi.org/10.1002/hep.32380openalex-snapshot
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
inferred← citeshttps://doi.org/10.1002/hep.32450openalex-snapshot
Making child’s play of tolerance: Defining the immune‐viral interplay during combination entecavir and pegylated interferon therapy for immune‐tolerant hepatitis B infection
inferred← citeshttps://doi.org/10.1002/hep.32634openalex-snapshot
HBV transcription and translation persist despite viral suppression in HBV‐HIV co‐infected patients on antiretroviral therapy
inferred← citeshttps://doi.org/10.1002/hep.32716openalex-snapshot
Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes
inferred← citeshttps://doi.org/10.1002/hep4.1281openalex-snapshot
Hepatitis B Treatment: What We Know Now and What Remains to Be Researched
inferred← citeshttps://doi.org/10.1002/hep4.1595openalex-snapshot
Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso
inferred← citeshttps://doi.org/10.1002/hep4.1623openalex-snapshot
Point Shear-Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver-Related Events in Patients With Chronic Viral Hepatitis
inferred← citeshttps://doi.org/10.1002/hep4.1918openalex-snapshot
A multi‐analyte cell‐free DNA–based blood test for early detection of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/hep4.2064openalex-snapshot
Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy
inferred← citeshttps://doi.org/10.1002/hsr2.70257openalex-snapshot
Propensity Score Matching Analysis for Alcohol‐Related Liver Disease
inferred← citeshttps://doi.org/10.1002/ijc.25382openalex-snapshot
Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic hepatitis B patients whose initial tumor was successfully ablated
inferred← citeshttps://doi.org/10.1002/ijc.31393openalex-snapshot
Etiology of hepatocellular carcinoma in W est A frica, a case–control study
inferred← citeshttps://doi.org/10.1002/ijc.31544openalex-snapshot
Herbal medicine containing aristolochic acid and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection
inferred← citeshttps://doi.org/10.1002/ijc.33051openalex-snapshot
Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL‐HBV and HCV studies
inferred← citeshttps://doi.org/10.1002/ijc.34492openalex-snapshot
Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL‐HBV and REVEAL‐HCV cohort studies
inferred← citeshttps://doi.org/10.1002/ila2.24openalex-snapshot
Significant histological changes are not rare in indeterminate‐phase chronic hepatitis B patients with hepatitis B e antigen‐negative and normal alanine aminotransferase levels
inferred← citeshttps://doi.org/10.1002/jcph.351openalex-snapshot
Entecavir plus adefovir combination therapy versus lamivudine add‐on adefovir for lamivudine‐resistant chronic hepatitis B: A meta‐analysis
inferred← citeshttps://doi.org/10.1002/jev2.12040openalex-snapshot
Efficient and reproducible depletion of hepatitis B virus from plasma derived extracellular vesicles
inferred← citeshttps://doi.org/10.1002/jgh3.12443openalex-snapshot
Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jgh3.70055openalex-snapshot
Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1002/jmv.20822openalex-snapshot
Characterization of viral kinetics in patients with hepatitis B e antigen‐positive chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.20934openalex-snapshot
Variations in the core promoter/pre‐core region in HBV genotype C in Japanese and Northern Vietnamese patients
inferred← citeshttps://doi.org/10.1002/jmv.21078openalex-snapshot
The increasing prevalence of hepatitis delta virus (HDV) infection in South London
inferred← citeshttps://doi.org/10.1002/jmv.21117openalex-snapshot
Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1002/jmv.21294openalex-snapshot
Prevalence of HBV genotypes in Central and Eastern Europe
inferred← citeshttps://doi.org/10.1002/jmv.21402openalex-snapshot
Association of lamivudine‐resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.21477openalex-snapshot
Validation of a sensitive and specific real‐time PCR for detection and quantitation of hepatitis B virus covalently closed circular DNA in plasma of chronic hepatitis B patients
inferred← citeshttps://doi.org/10.1002/jmv.21577openalex-snapshot
Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection
inferred← citeshttps://doi.org/10.1002/jmv.21686openalex-snapshot
Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values
inferred← citeshttps://doi.org/10.1002/jmv.21898openalex-snapshot
Efficacy of adefovir add‐on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine‐resistant chronic hepatitis B
inferred← citeshttps://doi.org/10.1002/jmv.22048openalex-snapshot
High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe
showing the first 200 of 3018 · page through all 3018
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.